Drugs /

busulfan

Back to Drugs List

Overview

Generic Name(s):
busulfan
Trade Name(s):
Misulban, Busulfex, Myleran, Mitosan, Mielucin, and Misulfan
NCI Definition [1]:
A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties. Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA. Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)

Clinical Trials

View Clinical Trials for busulfan

Busulfan has been investigated in 47 clinical trials, of which 36 are open and 11 are closed. Of the trials investigating busulfan, 8 are phase 1 (6 open), 9 are phase 1/phase 2 (8 open), 24 are phase 2 (18 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open).

Complex karyotype, Very Complex karyotype, and del(5)(q10) are the most frequent biomarker inclusion criteria for busulfan clinical trials.

Acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia are the most common diseases being investigated in busulfan clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Busulfan
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Busulfan
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating busulfan and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
750, 1,4-di(methylsulfonyloxy)butane, 1,4-butanediol dimethylsulfonate, methanesulfonic acid, tetramethylene ester, busulphan, 1,4-di(methanesulfonyloxy)butane, 1,4-butanediol dimethanesulfonate, 1,4-bis(methanesulfonoxy)butane, wr-19508, 1,4-bitanediol dimethanesulfonate esters, 1,4-dimesyloxybutane, tetramethylene bis(methanesulfonate), busulfan, 1,4-di(methylsulfonyloxy)butane, busulphan, myléran, busulfan (product), bussulfam, 1, 4-bis[methanesulfonoxy]butane, 1,4-dimethanesulfonoxybutane, bus, myeleukon, gt 41, cb 2041, methanesulfonic acid, tetramethylene ester, 1,4-butanediol dimethylsulfonate, busulfan (substance), joacamine, bu, cb-2041, gt-41, mylecytan, 1,4-bitanediol dimethanesulfonate esters, 1,4-butanediol, dimethanesulfonate, busulfan [chemical/ingredient], tetramethylene bis(methanesulfonate), busulfan, Misulfan, Misulban, Mielucin, Myleran, Mitosan, Busulfex, glyzophrol, 55-98-1, busulfano, myelosan, 1,4-di(methanesulfonyloxy)butane, 1,4-bis(methanesulfonoxy)butane, sulfabutin, myeloleukon, methanesulfonic acid tetramethylene ester, tetramethylene bis(methanesulfonate), tetramethylene bis[methanesulfonate], busulfanum, bsf, glyzophrol, busilvex
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C321
SNOMED ID [1]:
F-61A1F

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.